UNSPSC 51291801: Agomelatine

This classification denotes a serotonin antagonist and anxiolytic with the molecular formula C15H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 137R1N49AD, chemically known as acetamide, n-(2-(7-methoxy-1-naphthalenyl)ethyl)- but generally known as agomelatine, which bears US NIH Compound Identifier 82148. European Medicines Agency schedules Agomelatine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05286MIG.

UNSPSC 51291801 Agomelatine is a Commodity code that nominally designates a specific pharmaceutical active ingredient, yet recent state and local opportunities tagged under this code show minimal alignment with agomelatine itself. Instead, the code appears in solicitations for emergency-response pharmaceuticals, broader generic pharmaceutical and OTC product procurement through cooperative purchasing vehicles, and exploratory pharmacy benefit program redesign. State and local buyers using this code are acquiring naloxone and drug deactivation systems for community health initiatives, multi-source generic pharmaceuticals and OTC products through authorized wholesaler networks, and conducting market research on direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering procurement for member states and local government facilities (Minnesota MMCAP).

Recent activity spans Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; the RFP weighted price competitiveness at 75 percent and required vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson). The code's recent posting activity suggests opportunistic tagging rather than systematic procurement of agomelatine as a named pharmaceutical.